Advertisement

Topics

Companies Related to "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" [Most Relevant Company Matches] [Advanced Search Results] RSS

19:56 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Safety Immunogenicity Study Seronegative Subjects" Companies 1–25 of 2,800+

Extremely Relevant

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...


Relevant

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

PharmaTech Solutions Inc

PTS was founded in 1999 by a group of pharmaceutical research professionals who believed that a pioneering approach was required to solve the industry’s study enrollment problems. Through innovation and excellence, PTS has amassed the technology and experience to develop patient recruitment solutions that identify and address the core issues that can hinder enrollment. PTS understands that findi...


nTouch Research Corporation

nTouch Research Corporation is a leading provider of Phase II-IV clinical trials services delivering investigator selection, patient recruitment and study management services for pharmaceutical, CRO, and biotechnology industries.nTouch owns and operates 16 highly-rated research centers across the USA serving 250 private practice investigators. Our strength is our commitment to sponsors, investigat...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

Atlantic Life Sciences, Inc

Atlantic Life Sciences, Inc., Provider of Tailored Clinical Services ALS Inc. is located in Montreal.It is one of the world-class CRO where the Experience, the Expertise and the Strategic Project Management create a value addition for the study success. Since its inception, Atlantic Life Sciences Inc. accomplishes clinical studies with a top quality. Each study is unique. Since 2003, ALS Inc. cond...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

International Pharmaceutical Research Center

International Pharmaceutical Research Center the commitment to unparalleled Quality Research. Our strength is our recognition from sponsors, investigators, and study subjects in conducting each study with dedication and a personal touch, while maintaining strict compliance with good clinical practice.

Rapid Medical Research, Inc.

Rapid Medical Research, Inc., (RMR) is a free-standing, dedicated, multi-therapeutic clinical research center. Our professional research team includes an executive director, two physicians including a full-time onsite internist and 1 part-time OB/GYN, a regulatory specialist, four nurse coordinators, two patient recruiters, two research assistants, and an office manager. We offer a wide range of s...

Clinical Research Associate

Clinical Research Associate, also known as a Monitor, is an individual that oversees the progress and conduct of a clinical trial. A clinical trial is usually implemented by physicians at a hospital, clinic, or physician's office. The CRA is required to oversee the initiation, progress, and conduct of the clinical trial to ensure the scientific integrity of the data collected, and the protection o...

Advanced Biomedical Research Incorporated

Advanced Biomedical Research, Inc. (ABR) Corporate Headquarters is located in Pennington, New Jersey adjacent to the Princeton biopharmaceutical research corridor. ABR is a full service CRO offering an integrated package of customized services including clinical study protocol design, project management and study monitoring, quality assurance auditing, medical safety monitoring, biostatistics and...

Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Bost...

Phase Forward Incorporated

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Sc...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

ProFibrix B.V.

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant in development to stop bleeding after or during surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, is stable at room temperature, and has shown to be safe and efficacious...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian S...

Smithers Avanza

Smithers Avanza is a contract research organization known for superior quality, on-time delivery, flexibility, and responsiveness. Our laboratories support the pharmaceutical and chemical industries. At our GLP, cGMP, and AAALAC accredited facilities, our Development Services group offers general toxicology, safety pharmacology, vaccine safety testi...

TEXCELL

TEXCELL, a spin-off company of the Pasteur Institute, is based in Evry Genopole in more than 16,000 sq. ft of offices and BSL2/BSL3 laboratory facilities. TEXCELL offers GLP/GMP compliant services for viral safety, mycoplasma testing, and bioanalysis (TK/PK, immunogenicity, biomarkers, potency).


More From BioPortfolio on "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks